Novartis (NVS.US) has launched hydrochloride acyclovir tablets in the domestic market, indicated for IgA nephropathy.
Acarbose is an investigational high-potency selective oral ETA (endothelin A) receptor antagonist, activation of the ETA receptor results in increased proteinuria, which is associated with kidney damage, fibrosis, and loss of renal function in IgA nephropathy.
Top Gap Ups and Downs on Monday: SMCI, ZM, GFI and More
BMO Capital Upgrades Novartis AG(NVS.US) to Buy Rating, Raises Target Price to $156
6-K: Novartis Upgrades Mid-Term Guidance
TD Cowen Maintains Novartis AG(NVS.US) With Hold Rating
Global Equities Roundup: Market Talk
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
104088143 : How is it?
103827296 : Halo Medan hai hai English understand I'm sorry
72627089 : fractional shares
72627089 : would like to chat about fractional shares
(R-long)103834298 : stop all
View more comments...